Glomerular Disease in Cirrhosis

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 360-371

  Poole, Brian D ^a   Schrier, Robert W ^a   Jani, Alkesh ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cirrhosis; globulins; Glomerular disease; Glomerulopathies; Liver transplant

Indexed keywords

EID: 84889497705     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch29     Document Type: Chapter

References (132)

1. Flint A. Clinical report on hydroperitoneum, based on an analysis of 46 cases. Am J Med Sci 1863; 45:306-9.
2. Newell GC. Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis. Am J Kidney Dis 1987; 9:183-90.
3. Fisher EAH, Hellstrom HR. The membranous and proliferative glomerulonephritis of hepatic cirrhosis. Am J Pathol 1959; 32:48.
4. Bloodworth JM Jr, Sommers SC. "Cirrhotic glomerulosclerosis", a renal lesion associated with hepatic cirrhosis. Lab Invest 1959; 8:962-78.
5. Sakaguchi H, Dachs S, Grishman E, Paronetto F, Salomon M, Churg J. Hepatic glomerulosclerosis. An electron microscopic study of renal biopsies in liver diseases. Lab Invest 1965; 14:533-45.
6. Salomon MI, Sakaguchi H, Churg J et al. Renal lesions in hepatic disease: a study based on kidney biopsies. Arch Intern Med 1965; 115:704-9.
7. Callard P, Feldmann G, Prandi D et al. Immune complex type glomerulonephritis in cirrhosis of the liver. Am J Pathol 1975; 80:329-40.
8. Nochy D, Callard P, Bellon B, Bariety J, Druet P. Association of overt glomerulonephritis and liver disease: a study of 34 patients. Clin Nephrol 1976; 6:422-7.
9. Nakamoto Y, Iida H, Kobayashi K et al. Hepatic glomerulonephritis. Characteristics of hepatic IgA glomerulonephritis as the major part. Virchows Arch A Pathol Anat Histol 1981; 392:45-54.
10. Kawaguchi K, Koike M. Glomerular lesions associated with liver cirrhosis: an immunohistochemical and clinicopathologic analysis. Hum Pathol 1986; 17:1137-43.
11. Axelsen RA, Crawford DH, Endre ZH et al. Renal glomerular lesions in unselected patients with cirrhosis undergoing orthotopic liver transplantation. Pathology 1995; 27:237-46.
12. Crawford DH, Endre ZH, Axelsen RA et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992; 19:339-44.
13. Johnson RJ, Gretch DR, Yamabe H et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993; 328:465-70.
14. Sinniah R. Heterogeneous IgA glomerulonephropathy in liver cirrhosis. Histopathology 1984; 8:947-62.
15. Fukuda Y. Renal glomerular changes associated with liver cirrhosis. Acta Pathol Jpn 1982; 32:561-74.
16. Stehman-Breen C, Willson R, Alpers CE, Gretch D, Johnson RJ. Hepatitis C virus-associated glomerulonephritis. Curr Opin Nephrol Hypertens 1995; 4:287-94.
17. Praga M, Costa JR, Shandas GJ, Martinez MA, Miranda B, Rodicio JL. Acute renal failure in cirrhosis associated with macroscopic hematuria of glomerular origin. Arch Intern Med 1987; 147:173-4.
18. Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63:2254-61.
19. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998; 339:1448-56.
20. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123:754-62.
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-62.
22. Levey AS. Clinical practice. Nondiabetic kidney disease. N Engl J Med 2002; 347:1505-11.
23. Ohnishi A, Murakami S, Harada M et al. Renal and hormonal responses to repeated treatment with enalapril in non-azotemic cirrhosis with ascites. J Hepatol 1994; 20:223-30.
24. Gentilini P, Romanelli RG, La Villa G et al. Effects of lowdose captopril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology 1993; 104:588-94.
25. Vlachogiannakos J, Tang AK, Patch D, Burroughs AK. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut 2001; 49:303-8.
26. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-60.
27. Schneider AW, Kalk JF, Klein CP. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis. Hepatology 1999; 29:334-9.
28. Berger J, Yaneva H, Nabarra B. Glomerular changes in patients with cirrhosis of the liver. Adv Nephrol Necker Hosp 1977; 7:3-14.
29. Waldherr R, Rambausek M, Duncker WD, Ritz E. Frequency of mesangial IgA deposits in a non-selected autopsy series. Nephrol Dial Transplant 1989; 4:943-6.
30. Woodroffe AJ. IgA, glomerulonephritis and liver disease. Aust NZ J Med 1981; 11(Suppl. 1):109-11.
31. Smith SM, Hoy WE. Frequent association of mesangial glomerulonephritis and alcohol abuse: a study of 3 ethnic groups. Mod Pathol 1989; 2:138-43.
32. Amore A, Coppo R, Roccatello D et al. Experimental IgA nephropathy secondary to hepatocellular injury induced by dietary deficiencies and heavy alcohol intake. Lab Invest 1994; 70:68-77.
33. Amore A, Roccatello D, Picciotto G et al. Processing of IgA aggregates in a rat model of chronic liver disease. Clin Immunol Immunopathol 1997; 84:107-14.
34. Bene MC, De Korwin JD, Hurault de Ligny B, Aymard B, Kessler M, Faure GC. IgA nephropathy and alcoholic liver cirrhosis. A prospective necropsy study. Am J Clin Pathol 1988; 89:769-73.
35. Montoliu J, Darnell A, Torras A, Revert L. Glomerular disease in cirrhosis of the liver: low frequency of IgA deposits. Am J Nephrol 1986; 6:199-205.
36. Aggarwal M, Manske CL, Lynch PJ, Paller MS. Henoch-Schönlein vasculitis as a manifestation of IgA-associated disease in cirrhosis. Am J Kidney Dis 1992; 20:400-2.
37. Floege J, Feehally J. IgA nephropathy: recent developments. J Am Soc Nephrol 2000; 11:2395-403.
38. Kokubo T, Hiki Y, Iwase H et al. Protective role of IgA1 glycans against IgA1 self-aggregation and adhesion to extracellular matrix proteins. J Am Soc Nephrol 1998; 9:2048-54.
39. Roccatello D, Picciotto G, Coppo R et al. Clearance of polymeric IgA aggregates in humans. Am J Kidney Dis 1989; 14:354-60.
40. Roccatello D, Picciotto G, Torchio M et al. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors. Lab Invest 1993; 69:714-23.
41. Emancipator SN, Gallo GR, Razaboni R, Lamm ME. Experimental cholestasis promotes the deposition of glomerular IgA immune complexes. Am J Pathol 1983; 113:19-26.
42. Westerhuis R, Van Zandbergen G, Verhagen NA, Klar-Mohamad N, Daha MR, van Kooten C. Human mesangial cells in culture and in kidney sections fail to express Fc alpha receptor (CD89). J Am Soc Nephrol 1999; 10:770-8.
43. Peruzzi L, Amore A, Cirina P et al. Integrin expression and IgA nephropathy: in vitro modulation by IgA with altered glycosylation and macromolecular IgA. Kidney Int 2000; 58:2331-40.
44. Amore A, Conti G, Cirina P et al. Aberrantly glycosylated IgA molecules downregulate the synthesis and secretion of vascular endothelial growth factor in human mesangial cells. Am J Kidney Dis 2000; 36:1242-52.
45. Nikolova EB, Tomana M, Russell MW. The role of the carbohydrate chains in complement (C3) fixation by solidphase-bound human IgA. Immunology 1994; 82:321-7.
46. Zwirner J, Burg M, Schulze M et al. Activated complement C3: a potentially novel predictor of progressive IgA nephropathy. Kidney Int 1997; 51:1257-64.
47. Amore A, Cirina P, Conti G, Brusa P, Peruzzi L, Coppo R. Glycosylation of circulating IgA in patients with IgA nephropathy modulates proliferation and apoptosis of mesangial cells. J Am Soc Nephrol 2001; 12:1862-71.
48. Rekola S, Bergstrand A, Bucht H. Deterioration of GFR in IgA nephropathy as measured by 51Cr-EDTA clearance. Kidney Int 1991; 40:1050-4.
49. Bartosik LP, Lajoie G, Sugar L, Cattran DC. Predicting progression in IgA nephropathy. Am J Kidney Dis 2001; 38:728-35.
50. Haas M. Histologic subclassification of IgA nephropathy: a clinicopathologic study of 244 cases. Am J Kidney Dis 1997; 29:829-42.
51. Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analyses. Am J Kidney Dis 1991; 18:12-19.
52. Szeto CC, Lai FM, To KF et al. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med 2001; 110:434-7.
53. Cattran DC, Greenwood C, Ritchie S. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: a comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 1994; 23:247-54.
54. Rekola S, Bergstrand A, Bucht H. Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents. Nephron 1991; 59:57-60.
55. Praga M, Gutierrez E, Gonzalez E, Morales E, Hernandez E. Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003; 14:1578-83.
56. Tamura S, Ueki K, Ideura H et al. Corticosteroid therapy in patients with IgA nephropathy and impaired renal function. Clin Nephrol 2001; 55:192-5.
57. Kobayashi Y, Hiki Y, Fujii K, Kurokawa A, Tateno S. Moderately proteinuric IgA nephropathy: prognostic prediction of individual clinical courses and steroid therapy in progressive cases. Nephron 1989; 53:250-6.
58. Pozzi C, Andrulli S, Del Vecchio L et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol 2004; 15:157-63.
59. Pozzi C, Bolasco PG, Fogazzi GB et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 1999; 353(9156):883-7.
60. Tumlin JA, Lohavichan V, Hennigar R. Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol Dial Transplant 2003; 18:1321-9.
61. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE. A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 1994; 331:1194-9.
62. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999; 10:1772-7.
63. Pettersson EE, Rekola S, Berglund L et al. Treatment of IgA nephropathy with omega-3-polyunsaturated fatty acids: a prospective, double-blind, randomized study. Clin Nephrol 1994; 41:183-90.
64. Bennett WM, Walker RG, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a twoyear prospective trial. Clin Nephrol 1989; 31:128-31.
65. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 1997; 8:1739-44.
66. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244(4902):359-62.
67. Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244(4902):362-4.
68. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29:908-14.
69. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42:631-57.
70. Pawlotsky JM, Ben Yahia M, Andre C et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994; 19:841-8.
71. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1992; 16:244-5.
72. Herrero C, Vicente A, Bruguera M et al. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet 1993; 341(8848):788-9.
73. Haddad J, Deny P, Munz-Gotheil C et al. Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339(8789): 321-3.
74. Misiani R, Bellavita P, Fenili D et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992; 117:573-7.
75. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57:775-88.
76. Meltzer M, Franklin EC, Elias K, McCluskey RT, Cooper N. Cryoglobulinemia-a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med 1966; 40:837-56.
77. Gorevic PD, Kassab HJ, Levo Y et al. Mixed cryoglobulinemia: clinical aspects and long-term follow up of 40 patients. Am J Med 1980; 69:287-308.
78. Wong VS, Egner W, Elsey T, Brown D, Alexander GJ. Incidence, character and clinical relevance of mixed cryoglobulinaemia in patients with chronic hepatitis C virus infection. Clin Exp Immunol 1996; 104:25-31.
79. Lunel F, Musset L, Cacoub P et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994; 106:1291-300.
80. Adinolfi LE, Utili R, Attanasio V et al. Epidemiology, clinical spectrum and prognostic value of mixed cryoglobulinaemia in hepatitis C virus patients: a prospective study. Ital J Gastroenterol 1996; 28:1-9.
81. Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327:1490-5.
82. D'Amico G, Colasanti G, Ferrario F, Sinico RA. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989; 35:1004-14.
83. D'Amico G. Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 1998; 54:650-71.
84. Sansonno D, Gesualdo L, Manno C, Schena FP, Dammacco F. Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology 1997; 25:1237-44.
85. Ferri C, Monti M, La Civita L et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993; 82:3701-4.
86. Perl A, Gorevic PD, Ryan DH, Condemi JJ, Ruszkowski RJ, Abraham GN. Clonal B cell expansions in patients with essential mixed cryoglobulinaemia. Clin Exp Immunol 1989; 76:54-60.
87. Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR. Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 1995; 90:548-52.
88. Fornasieri A, Armelloni S, Bernasconi P et al. High binding of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular fibronectin: a mechanism for induction of in situ immune complex glomerulonephritis? Am J Kidney Dis 1996; 27:476-83.
89. Johnson RJ, Gretch DR, Couser WG et al. Hepatitis C virusassociated glomerulonephritis. Effect of alpha-interferon therapy. Kidney Int 1994; 46:1700-4.
90. Gopalani A, Ahuja TS. Prevalence of glomerulopathies in autopsies of patients infected with the hepatitis C virus. Am J Med Sci 2001; 322:57-60.
91. Davda R, Peterson J, Weiner R, Croker B, Lau JY. Membranous glomerulonephritis in association with hepatitis C virus infection. Am J Kidney Dis 1993; 22: 452-5.
92. Okada K, Takishita Y, Shimomura H et al. Detection of hepatitis C virus core protein in the glomeruli of patients with membranous glomerulonephritis. Clin Nephrol 1996; 45:71-6.
93. Stehman-Breen C, Alpers CE, Fleet WP, Johnson RJ. Focal segmental glomerular sclerosis among patients infected with hepatitis C virus. Nephron 1999; 81:37-40.
94. Herzenberg AM, Telford JJ, De Luca LG, Holden JK, Magil AB. Thrombotic microangiopathy associated with cryoglobulinemic membranoproliferative glomerulonephritis and hepatitis C. Am J Kidney Dis 1998; 31:521-6.
95. Markowitz GS, Cheng JT, Colvin RB, Trebbin WM, D'Agati VD. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9:2244-52.
96. Gonzalo A, Navarro J, Barcena R, Quereda C, Ortuno J. IgA nephropathy associated with hepatitis C virus infection. Nephron 1995; 69:354.
97. Usalan C, Erdem Y, Altun B et al. Rapidly progressive glomerulonephritis associated with hepatitis C virus infection. Clin Nephrol 1998; 49:129-31.
98. Tarantino A, Campise M, Banfi G et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995; 47:618-23.
99. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358(9286):958-65.
100. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
101. Misiani R, Bellavita P, Fenili D et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751-6.
102. Misiani R, Bellavita P, Baio P et al. Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin. Nephrol Dial Transplant 1999; 14:1558-60.
103. Rossi P, Bertani T, Baio P et al. Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy. Kidney Int 2003; 63:2236-41.
104. Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18:1573-80.
105. Kimmel PAM, Moore J Jr. Viral glomerular diseases. In: Schrier R, ed. Diseases of the Kidney and Urinary Tract. Philadelphia: Lippincott Williams & Wilkins, 2001; 1633-64.
106. Alter MJ, Hadler SC, Margolis HS et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. J Am Med Assoc 1990; 263:1218-22.
107. Combes B, Shorey J, Barrera A et al. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971; 2(7718):234-7.
108. Maggiore Q, Bartolomeo F, L'Abbate A, Misefari V. HBsAg glomerular deposits in glomerulonephritis: fact or artifact? Kidney Int 1981; 19:579-86.
109. Hirose H, Udo K, Kojima M et al. Deposition of hepatitis B e antigen in membranous glomerulonephritis: identification by F(ab')2 fragments of monoclonal antibody. Kidney Int 1984; 26:338-41.
110. Lai FM, Lai KN, Tam JS, Lui SF, To KF, Li PK. Primary glomerulonephritis with detectable glomerular hepatitis B virus antigens. Am J Surg Pathol 1994; 18:175-86.
111. Lin CY. Hepatitis B virus-associated membranous nephropathy: clinical features, immunological profiles and outcome. Nephron 1990; 55:37-44.
112. Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990; 54:12-17.
113. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alphainterferon. Kidney Int 1995; 47:225-30.
114. Jennette JAF, Falk RJ. Renal involvement in systemic disease. In: Greenberg A, ed. Primer on Kidney Diseases. San Diego: Academic Press, 1998; 200-7.
115. Gocke DJ, Hsu K, Morgan C, Bombardieri S, Lockshin M, Christian CL. Association between polyarteritis and Australia antigen. Lancet 1970; 2(7684):1149-53.
116. Michalak T. Immune complexes of hepatitis B surface antigen in the pathogenesis of periarteritis nodosa. A study of seven necropsy cases. Am J Pathol 1978; 90:619-32.
117. Guillevin L, Lhote F, Leon A, Fauvelle F, Vivitski L, Trepo C. Treatment of polyarteritis nodosa related to hepatitis B virus with short term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients. J Rheumatol 1993; 20:289-98.
118. Shear L, Bonkowsky HL, Gabuzda GJ. Renal tubular acidosis in cirrhosis. A determinant of susceptibility to recurrent hepatic precoma. N Engl J Med 1969; 280:1-7.
119. Caregaro L, Lauro S, Ricci G, Merkel C, Milani L, Gatta A. Distal renal tubular acidosis in hepatic cirrhosis: clinical and pathogenetic study. Clin Nephrol 1981; 15:143-7.
120. Gentilini P, Laffi G, Buzzelli G et al. Functional renal alterations in chronic liver diseases. Digestion 1980; 20: 73-8.
121. Golding PL. Renal tubular acidosis in chronic liver disease. Postgrad Med J 1975; 51:550-6.
122. Smith PM, Middleton JE, Williams R. Renal tubular acidosis and cirrhosis. Postgrad Med J 1967; 43:439-42.
123. Golding PL, Mason AS. Renal tubular acidosis and autoimmune liver disease. Gut 1971; 12:153-7.
124. Golding PL, Smith M, Williams R. Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med 1973; 55:772-82.
125. Pares A, Rimola A, Bruguera M, Mas E, Rodés J. Renal tubular acidosis in primary biliary cirrhosis. Gastroenterology 1981; 80:681-6.
126. Morgan HG, Stewart WK, Lowe KG, Stowers JM, Johnstone JH. Wilson's disease and the Fanconi syndrome. Q J Med 1962; 31:361-84.
127. Wilson DM, Goldstein NP. Bicarbonate excretion in Wilson's disease (hepatolenticular degeneration). Mayo Clin Proc 1974; 49:394-400.
128. Walshe JM. Effect of penicillamine on failure of renal acidification in Wilson's disease. Lancet 1968; 1(7546): 775-8.
129. Leu ML, Strickland GT, Gutman RA. Renal function in Wilson's disease: response to penicillamine therapy. Am J Med Sci 1970; 260:381-98.
130. Eaves ER, Korman MG. Cholestyramine induced hyperchloremic metabolic acidosis. Aust NZ J Med 1984; 14:670-2.
131. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity. J Am Soc Nephrol 2002; 13:2160-70.
132. Leeson PM, Fourman P. A disorder of copper metabolism treated with penicillamine in a patient with primary biliary cirrhosis and renal tubular acidosis. Am J Med 1967; 43:620-35.